MREO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.13%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $576,213.84

Mereo BioPharma Group Insider Trading History Chart

Mereo BioPharma Group Share Price & Price History

^$3.60

▲ +0.12 (3.45%)

As of 06/28/2024 01:00 AM ET

Days: 30 | 90 | 365

Elon Musk: THIS will be bigger than Tesla

From Paradigm Press | Ad

If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.

See all the details you need here.

Mereo BioPharma Group Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/25/2024	Charles Sermon	General Counsel	Sell	14,202	$3.69	$52,405.38	216,574
6/25/2024	Christine Ann Fox	CFO	Sell	12,990	$3.69	$47,933.10	87,010
6/25/2024	Denise Scots-Knight	CEO	Sell	40,712	$3.69	$150,227.28	801,791
6/25/2024	John A Lewicki	Insider	Sell	7,416	$3.69	$27,365.04	65,587
5/22/2024	Alexandra Hughes-Wilson	Insider	Sell	100,432	$2.97	$298,283.04	32,568

Elon Musk’s chilling warning for humanity

From The Freeport Society | Ad

The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.

Go here to see why.

SEC Filings (Institutional Ownership Changes) for Mereo BioPharma Group (NASDAQ:MREO)

62.83% of Mereo BioPharma Group stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Mereo BioPharma Group Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/16/2024	Janus Henderson Group PLC	5,120,573	$16.95M	0.0%	N/A	3.651%
5/16/2024	Knoll Capital Management LLC	260,470	$0.86M	0.5%	+62.3%	0.186%
5/15/2024	Price T Rowe Associates Inc. MD	991,971	$3.27M	0.0%	N/A	0.707%
5/13/2024	Index Fund Advisors Inc.	30,000	$99K	0.0%	N/A	0.021%
5/9/2024	Monaco Asset Management SAM	405,000	$1.34M	0.4%	-40.1%	0.324%
5/8/2024	Advisors Preferred LLC	8,262	$28K	0.0%	N/A	0.007%
5/7/2024	SG Americas Securities LLC	16,221	$54K	0.0%	N/A	0.013%
5/1/2024	BNP Paribas Financial Markets	17,435	$58K	0.0%	+581,066.7%	0.014%
2/15/2024	Forefront Analytics LLC	36,124	$83K	0.0%	-45.0%	0.029%
2/14/2024	Rubric Capital Management LP	13,552,997	$31.31M	0.6%	+16.7%	10.843%
2/13/2024	NEOS Investment Management LLC	351,905	$0.81M	0.1%	+751.5%	0.282%
2/9/2024	Primecap Management Co. CA	54,000	$0.13M	0.0%	-31.6%	0.043%
2/7/2024	Monaco Asset Management SAM	676,494	$1.56M	0.5%	+13.6%	0.541%
2/2/2024	Golden State Equity Partners	20,300	$47K	0.0%	+41.0%	0.016%
1/31/2024	abrdn plc	1,551,082	$3.58M	0.0%	N/A	1.241%
1/18/2024	Clear Harbor Asset Management LLC	59,754	$0.14M	0.0%	-6.3%	0.048%
11/15/2023	Tejara Capital Ltd	3,215,001	$4.15M	2.4%	+5.8%	2.572%
11/15/2023	Rock Springs Capital Management LP	7,676,481	$9.90M	0.3%	+9.0%	6.142%
11/15/2023	Adage Capital Partners GP L.L.C.	800,000	$1.03M	0.0%	N/A	0.640%
11/14/2023	683 Capital Management LLC	6,000,000	$7.74M	0.6%	+11.1%	4.800%
11/14/2023	Primecap Management Co. CA	79,000	$0.10M	0.0%	-49.9%	0.063%
11/13/2023	Tejara Capital Ltd	3,215,001	$4.15M	3.1%	+5.8%	2.572%
11/9/2023	Formidable Asset Management LLC	331,914	$0.43M	0.1%	N/A	0.266%
11/8/2023	Forefront Analytics LLC	65,649	$85K	0.0%	-20.7%	0.053%
11/7/2023	Monaco Asset Management SAM	595,729	$0.77M	0.2%	-15.6%	0.477%
11/6/2023	Privium Fund Management UK Ltd	24,726	$32K	0.0%	-86.0%	0.020%
10/26/2023	Clear Harbor Asset Management LLC	63,754	$82K	0.0%	+12.3%	0.051%
8/14/2023	683 Capital Management LLC	5,400,000	$7.13M	0.5%	+170.0%	4.320%
8/14/2023	Rock Springs Capital Management LP	7,042,391	$9.30M	0.2%	+12.8%	5.634%
8/14/2023	Mangrove Partners	5,531,547	$7.30M	0.5%	N/A	4.426%
8/11/2023	Rubric Capital Management LP	11,616,120	$15.33M	0.7%	+12.1%	9.294%
8/11/2023	Tejara Capital Ltd	3,037,971	$4.01M	2.0%	+24.7%	2.431%
8/8/2023	Monaco Asset Management SAM	705,729	$0.93M	0.3%	-46.4%	0.565%
8/3/2023	PFG Investments LLC	31,500	$42K	0.0%	-33.7%	0.025%
7/26/2023	Privium Fund Management B.V.	177,200	$0.23M	0.1%	N/A	0.142%
7/21/2023	Clear Harbor Asset Management LLC	56,754	$75K	0.0%	-29.7%	0.045%
5/12/2023	Tejara Capital Ltd	2,435,806	$1.72M	0.9%	+11.3%	1.949%
5/12/2023	Forefront Analytics LLC	83,700	$59K	0.0%	+13.9%	0.067%
5/11/2023	PFG Investments LLC	47,500	$34K	0.0%	N/A	0.038%
5/9/2023	Formidable Asset Management LLC	331,914	$0.23M	0.0%	+15.2%	0.266%
2/14/2023	683 Capital Management LLC	125,000	$94K	0.0%	N/A	0.100%
2/13/2023	Forefront Analytics LLC	73,500	$55K	0.0%	-34.8%	0.059%
2/3/2023	Monaco Asset Management SAM	2,049,661	$1.54M	0.4%	+998.1%	1.640%
1/31/2023	Monaco Asset Management SAM	2,049,661	$1.54M	0.5%	+998.1%	1.640%
1/20/2023	Clear Harbor Asset Management LLC	84,000	$63K	0.0%	-42.1%	0.067%
11/14/2022	Point72 Asset Management L.P.	9,829,354	$8.46M	0.0%	-2.1%	7.864%
11/14/2022	Clearline Capital LP	3,957,135	$3.41M	0.4%	+29.4%	3.166%
11/14/2022	Rubric Capital Management LP	10,366,120	$8.93M	0.4%	-38.1%	8.294%
11/14/2022	Forefront Analytics LLC	112,800	$96K	0.1%	+48.7%	0.090%
11/7/2022	Virtu Financial LLC	33,880	$29K	0.0%	N/A	0.027%
11/3/2022	Barclays PLC	39,470	$34K	0.0%	+97.4%	0.032%
11/1/2022	Privium Fund Management UK Ltd	177,200	$0.15M	0.2%	N/A	0.142%
10/31/2022	Monaco Asset Management SAM	186,656	$0.16M	0.1%	N/A	0.160%
10/25/2022	Clear Harbor Asset Management LLC	145,000	$0.13M	0.0%	-10.5%	0.124%
8/16/2022	Formidable Asset Management LLC	275,556	$0.31M	0.1%	N/A	0.236%
8/16/2022	DAFNA Capital Management LLC	1,096,513	$1.23M	0.3%	-9.9%	0.937%
8/15/2022	Clearline Capital LP	3,058,596	$3.43M	0.4%	+135.0%	2.615%
8/15/2022	Point72 Asset Management L.P.	10,035,970	$11.24M	0.0%	-12.7%	8.579%
8/12/2022	Ikarian Capital LLC	615,856	$0.20M	0.0%	-32.8%	0.526%
8/11/2022	Primecap Management Co. CA	321,660	$0.36M	0.0%	-2.8%	0.275%
8/10/2022	Forefront Analytics LLC	75,850	$83K	0.0%	N/A	0.065%
7/25/2022	Silverarc Capital Management LLC	156,195	$0.18M	0.1%	-33.7%	0.134%
7/20/2022	Clear Harbor Asset Management LLC	162,000	$0.19M	0.0%	+589.4%	0.138%
5/17/2022	Rock Springs Capital Management LP	6,074,943	$6.80M	0.2%	+8.8%	5.193%
5/16/2022	Clearline Capital LP	1,301,783	$1.46M	0.2%	+89.7%	1.113%
5/16/2022	J. Goldman & Co LP	217,051	$0.24M	0.0%	+221.6%	0.186%
5/16/2022	Eversept Partners LP	370,170	$0.42M	0.0%	+42.7%	0.316%
5/16/2022	Maven Securities LTD	544,458	$0.61M	0.0%	+72.6%	0.465%
2/15/2022	Rubric Capital Management LP	14,914,447	$23.86M	1.1%	+32.0%	22.001%
2/15/2022	Sender Co & Partners Inc.	333,904	$0.53M	0.3%	N/A	0.493%
2/15/2022	Shay Capital LLC	48,052	$77K	0.0%	N/A	0.071%
2/15/2022	Commodore Capital LP	1,954,970	$3.13M	0.7%	-0.9%	2.884%
2/14/2022	Clearline Capital LP	686,292	$1.10M	0.1%	N/A	1.012%
2/14/2022	Bluefin Capital Management LLC	37,300	$60K	0.0%	N/A	0.055%
2/14/2022	Point72 Asset Management L.P.	10,610,000	$16.98M	0.1%	+6.4%	15.651%
2/14/2022	Eversept Partners LP	259,470	$0.42M	0.0%	-71.2%	0.383%
2/14/2022	Maven Securities LTD	315,457	$0.51M	0.0%	N/A	0.465%
2/9/2022	Insight Advisors LLC PA	15,712	$25K	0.0%	-55.5%	0.023%
2/8/2022	ProShare Advisors LLC	15,646	$25K	0.0%	N/A	0.023%
1/21/2022	Clear Harbor Asset Management LLC	17,000	$27K	0.0%	N/A	0.025%
11/16/2021	Suvretta Capital Management LLC	9,142,067	$22.12M	0.4%	+5.7%	13.486%
11/16/2021	Schonfeld Strategic Advisors LLC	820,793	$1.99M	0.0%	-38.1%	1.211%
11/16/2021	Millennium Management LLC	1,434,544	$3.47M	0.0%	-13.8%	2.116%
11/16/2021	Commodore Capital LP	1,972,958	$4.78M	1.3%	-4.2%	2.910%
11/15/2021	Point72 Asset Management L.P.	9,975,000	$24.14M	0.1%	-1.3%	14.714%
11/15/2021	Rock Springs Capital Management LP	4,832,978	$11.70M	0.2%	+6.4%	7.129%
11/15/2021	Eversept Partners LP	899,569	$2.18M	0.2%	N/A	1.327%
11/12/2021	Renaissance Technologies LLC	398,900	$0.97M	0.0%	+39.9%	0.588%
11/12/2021	Rubric Capital Management LP	11,300,000	$27.35M	0.8%	+99.6%	16.669%
11/12/2021	Jump Financial LLC	32,788	$79K	0.0%	-78.4%	0.048%
11/12/2021	Primecap Management Co. CA	339,600	$0.82M	0.0%	-30.5%	0.501%
11/12/2021	Oppenheimer & Co. Inc.	19,000	$46K	0.0%	N/A	0.028%
11/5/2021	Resources Investment Advisors LLC.	36,043	$87K	0.0%	+177.3%	0.053%
11/2/2021	Valeo Financial Advisors LLC	22,506	$54K	0.0%	-30.8%	0.033%
8/27/2021	Endurant Capital Management LP	756,915	$2.40M	0.7%	-43.5%	1.117%
8/25/2021	Marshall Wace LLP	44,682	$0.14M	0.0%	-39.3%	0.066%
8/18/2021	Ikarian Capital LLC	944,308	$0.35M	0.0%	-17.6%	1.393%
8/17/2021	Perceptive Advisors LLC	1,696,068	$5.38M	0.1%	-71.7%	2.502%
8/17/2021	Logos Global Management LP	46,984	$0.15M	0.0%	N/A	0.069%
8/17/2021	Millennium Management LLC	1,663,950	$5.28M	0.0%	-35.7%	2.455%

Data available starting January 2016

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $3.60

$3.40

$3.61

50 Day Range

MA: $3.33

$2.74

$4.25

52 Week Range

Now: $3.60

$1.07

$4.50

Volume

1,278,950 shs

Average Volume

1,491,726 shs

Market Capitalization

$504.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Who are the company insiders with the largest holdings of Mereo BioPharma Group?: Mereo BioPharma Group's top insider investors include:
Denise Scots-Knight (CEO)
Charles Sermon (General Counsel)
Christine Ann Fox (CFO)
John A Lewicki (Insider)
Alexandra Hughes-Wilson (Insider)
Learn More about top insider investors at Mereo BioPharma Group.